NCT02393547

Lorcaserin for Preventing Weight Gain Among Smokers

Lorcaserin for Preventing Weight Gain Among Smokers Receiving Varenicline: A Pilot Study

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.

Detailed description

This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline. The investigators will obtain preliminary data on the efficacy of lorcaserin (10 mg twice daily) for 12 weeks in 20 adult weight-concerned cigarette smokers with a BMI of 27 to 40 simultaneously receiving 12 weeks of open-label varenicline and a behavioral intervention to assist with stopping smoking. Secondary aims will be weight, waist circumference, and smoking cessation.

Conditions

• Tobacco Use Disorder
• Weight Gain

Interventions

Type	Name	Description
DRUG	Varenicline	All subjects receive Varenicline
DRUG	Lorcaserin	All subjects receive Lorcaserin

Timeline

• Start date: 2013-09-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2015-03-19
• Last updated: 2017-06-06
• Results posted: 2017-06-06

Locations

1 site across 1 country: United States